New Genetic Test Could Diagnose Brain Tumours in 2 Hours
Researchers at the University of Nottingham have developed a new genetic test that can diagnose brain tumours in as little as 2 hours
The test, called ROBIN, uses PromethION nanopore sequencing to deliver rapid methylome classification. The researchers said results could be available intraoperatively, allowing clinicians to make faster, more informed decisions.
The same assay can also be used for next-day molecular profiling, including detection of single nucleotide, copy number, and structural variants.
DNA methylation-based classification is now essential for diagnosing and managing many brain tumour subtypes. Current diagnostic methods rely on additional microarray-based assays to detect pathognomonic somatic mutations and structural variants. These steps often delay final diagnosis.
Delays Cause Distress and Postpone Treatment
Due to the high capital costs, current analytic tests are restricted to specialist tertiary care centres with high throughput, requiring samples to be sent across regions. Tests are sent to centralised facilities, meaning that clinicians have to wait six to eight weeks or longer before they receive full results.
This delay can cause significant anxiety for patients and postpone the start of treatment.
New Test Offers 2-Hour Turnaround
In a study published in Neuro-Oncology , the Nottingham team of scientists and medics tested ROBIN's classifier performance on 50 prospective intraoperative cases.
ROBIN, a software tool based on the P2 PromethION nanopore sequencers
The test achieved a diagnostic turnaround time under 2 hours. Tumour classification began within minutes of sequencing.
It was able to detect single nucleotide variants, copy number variants, and structural variants in real time. In many cases, methylation classification and identification were achieved within a few hours of sequencing.
In 90% of classifiable cases, the test provided a complete integrated diagnosis within 24 hours. Its classifications matched the final diagnosis in 90% of cases.
ROBIN was able to provide a full integrated diagnosis, with a mean turnaround time of 24 hours for the ultra-fast pipeline. Classifier performance demonstrated concordance with the final integrated diagnosis in 90% of prospective cases.
Researchers say nanopore sequencing can improve diagnostic turnaround and offer reliable, clinically actionable intraoperative classification.
The test also requires minimal tissue, enabling diagnosis from small samples, such as those obtained via stereotactic biopsy.
"Revolutionary" Speed and Accuracy
Study co-author Dr Simon Paine, consultant neuropathologist at Nottingham University Hospital, noted both the speed and accuracy of the test. "It really is revolutionary," he said in a press release.
According to Cancer Research UK, about 12,700 people are diagnosed with brain tumours annually in the UK. More than 5000 die each year
Incidence has increased by 24% since the early 2000s. Ten-year survival remains low, at just 11%.
The Nottingham team believes that ROBIN could significantly improve care for thousands of UK patients each year. The researchers hope to see the test adopted across NHS trusts.
However, they stressed that clinical trials are needed to confirm its utility in routine practice.
The BRAIN MATRIX trial, funded by The Brain Tumour Charity, will assess how ROBIN can help match patients to personalised clinical trials.
Dr Simon Newman, chief scientific officer at the charity, said in a press release that rapid diagnosis could reduce uncertainty for patients and speed up access to care.
'The potential to combine so many separate tests into one and deliver at a local level is a game changer,' he said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Yili Secures Four World Dairy Innovation Awards at the 18th Global Dairy Congress
AMSTERDAM, June 23, 2025 /PRNewswire/ -- On June 18–19, the Global Dairy Congress 2025 was held in Amsterdam. At the forum, Dr. Ignatius Szeto, Assistant President of Yili Group, delivered a keynote speech titled "Innovating for a sustainable future" and shared Yili's latest innovative practices. On the opening day, the organizers unveiled the winners of the 2025 World Dairy Innovation Awards. Yili secured four World Dairy Innovation Awards and six commended Awards. Notably, Yili has claimed the World Dairy Innovation Awards for six consecutive years. Dr. Carolien van Loo, Head of Yili Innovation Center Europe, attended a roundtable forum on maternal and infant nutrition and breast milk research. Multiple star products from Yili's top infant formula brand, Pro-Kido, were featured as the Congress's officially designated products. At the Industry Leadership Forum, Dr. Ignatius Szeto systematically introduced Yili's global innovation practices across product innovation, maternal and infant nutrition, advanced dairy processing, and sustainable development. He emphasized: "Innovation is the driving force behind the sustainable prosperity of the dairy industry. Remaining consumer-centric, Yili dedicates itself to nutrition and health research across the full life cycle, keeps making core technological breakthroughs, and accelerates the commercialization of fundamental research outcomes—all of which contribute to the advancement of the global dairy sector." During the roundtable forum themed "Innovation in Pioneering a New Future for Global Maternal and Infant Health", Dr. Ignatius Szeto and Dr. Carolien van Loo engaged in in-depth discussions with experts including Jean-Christophe Kremer, Secretary-General of the International Special Dietary Foods Industries, and Richard Hall, Chair of FoodBev Media. The discussions focused on research about breast milk and maternal and infant nutrition. Dr. Carolien van Loo highlighted that Yili Innovation Center Europe, in collaboration with institutions such as Wageningen University and Donders Institute for Brain, Cognition and Behaviour, has conducted pioneering research on HMOs. Their breakthrough findings demonstrated HMOs' health benefits in enhancing immunity, protecting gut barrier function, preventing pathogen adhesion, and promoting cognitive development. The annual World Dairy Innovation Awards were announced at the event. This year, Yili Group secured four awards for its high-quality products and outstanding performance in innovation. Zhenlao Light Cream from Yijiahao Cheese won the Best Artisan Product, Joyday Crunchy Choco Lava was awarded Best Ice Cream, Yili's patented multi-enzymatic lactose-to-GOS technology: Boosting Gut Health in Qinghuo Adult Milk Powder claimed the Best Intolerance-Friendly Innovation, and Satine Carbon-Reduced Organic Milk won the Best CSR/Sustainability Initiative. Staying true to its philosophy of "No Innovation, No Future," Yili consistently increases its R&D investment to provide comprehensive nutrition solutions for consumers across the full life cycle. To date, Yili has established 15 innovation centers across Asia, Europe, and Oceania. Moving forward, Yili will continue to align its strategy with consumer needs, drive growth through technological innovation, and foster global partnerships to deliver enhanced health value for consumers worldwide, aiming to enable the sustainable prosperity of the dairy industry. View original content to download multimedia: SOURCE Yili Group Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Medscape
40 minutes ago
- Medscape
CMR in MINOCA Linked to Improved Diagnosis and Management
TOPLINE: In a prospective study of over 300 patients with myocardial infarction with nonobstructive coronary arteries (MINOCA), cardiovascular magnetic resonance (CMR) was associated with meaningful changes in clinical diagnosis and/or management in 63% of patients and a similar increase in diagnostic certainty. METHODOLOGY: Previous CMR studies in MINOCA have focused on radiologic yield — a limited metric that does not reflect real‐world clinical utility. Prospective data on patient care are lacking. This prospective study conducted in Australia and the UK assessed the impact of CMR on diagnosis and management in 320 patients with MINOCA (mean age, 55.6 years; 52% men) recruited between January 2019 and July 2023. Patients were included if they had a hospital admission with acute features consistent with the Fourth Universal Definition of Myocardial Infarction, no obstructive coronary artery disease on angiography, and a clinician assessment indicating acute myocardial infarction as the most likely presentation. The treating cardiologists completed a questionnaire before and after CMR to record their working diagnosis, rate diagnostic certainty on a 1-10 scale (10 = most certain), and specify intended management, including medications and follow-up testing. The primary endpoint was a composite of change in clinical diagnosis or management after CMR. TAKEAWAY: CMR was associated with a change in diagnosis or management in 63% of patients (P < .001), with diagnosis revised in 38% and management changed in 50%. Diagnostic certainty increased significantly from a median score of 6-8 after CMR (P < .001), and diagnostic confidence numerically increased in 63% of patients. The absence of coronary atheroma, a pre-CMR diagnostic certainty score ≤ 5, and early CMR (performed within 14 days of hospital presentation) independently predicted a change in diagnosis or management, with 80% of patients with all three predictors vs 40% of those with none meeting the primary outcome. Of 172 patients initially prescribed dual antiplatelet therapy, 66 (38%) had it deprescribed following CMR, yielding a number needed to test of 3. IN PRACTICE: 'Integration of CMR into diagnostic imaging pathways may be reasonable to augment clinical diagnosis and management; however, further cost-effectiveness analyses are now warranted,' the study authors wrote. SOURCE: This study was led by Adil Rajwani, PhD, of the Royal Perth Hospital, Perth, Australia. It was published online on June 13, 2025, in Heart. LIMITATIONS: The study was limited by the impracticality of conducting a bias-free randomized trial of CMR vs no CMR. It was also limited by the assessment of CMR's impact only immediately after imaging, potentially missing later clinical insights. Medication protocols were not standardized, and the limited use of additional diagnostics such as optical coherence tomography may have influenced the findings. DISCLOSURES: This study was funded by a grant from the Royal Perth Hospital Medical Research Foundation in Australia. The authors declared having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
2 hours ago
- Yahoo
Stourbridge care home donates life-saving equipment to school
A STOURBRIDGE care home has donated a potentially life-saving piece of equipment to a primary school. Parkfield Grange care home gifted a bleed control kit to Netherbrook Primary School. The kit, which contains equipment to stop severe bleeding, will be used in emergency situations. Catherine Marshall, assistant head teacher at Netherbrook Primary School, said: "We were absolutely thrilled when a parent of two of our pupils, who works at Parkfield Grange Care Home, shared our fundraising plans with Emily Hocking, the home admissions advisor. "Emily kindly reached out and generously donated a bleed control kit. "We cannot thank Parkfield Grange enough for helping us access this vital emergency equipment that could one day save lives. "This donation not only enhances the safety of our pupils and staff but also means we're better prepared to support our wider community in the event of an emergency." Emily Hocking, home admissions advisor at Parkfield Grange, said: "We are part of a vibrant and caring community and when our colleague informed us of Netherbrook's plan to raise funds for a bleed control kit, we were delighted to donate one. "Having such a kit in a community setting can save lives before paramedics arrive." Parkfield Grange, which is located on the Hagley Road in Stourbridge, offers 68 large en-suite bedrooms and six one-bedroom care suites, all furnished. The care suites include an en-suite bedroom, lounge, and kitchenette and although developed with couples in mind, are ideal for those looking for more space and privacy than a traditional care bedroom.
